Stay updated with breaking news from Recommendation Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Urges Shareholders to Protect Their Investment and the Future of Wyndham by Supporting Only Wyndham's Eight Highly-Qualified Director Nominees Encourages Shareholders to Visit StayWyndham.com for...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to...
Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the ...
Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize...
Germany - MorphoSys AG today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis' intention to submit a voluntary public...